Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.
The NCCN published its first guidelines for pediatric bone sarcoma, centering on Ewing sarcoma and other undifferentiated ...
The investigational radiopharmaceutical therapy RYZ101 (225Ac-DOTATATE) produced a statistically significant and clinically ...
With bispecifics, that’s extraordinarily rare. The incidence of ICANS with bispecifics is on the order of 5% or less, and ...
An expert panel discusses the case for de-escalating antibiotic therapy for pediatric patients who undergo hematopoietic cell transplantation. The conversation examines antimicrobial stewardship and ...
Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma. The NCCN published its first ...
Boccia, MD, FACP, founder of The Center for Cancer and Blood Disorders, clinical associate professor at MedStar Georgetown ...
The FDA has granted fast track designation to VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted PRO-XTEN® ...
A study of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with ...
The safety profile is one of the biggest advantages of CAR NK cells, and that is exciting for the field because NK cells do ...
Just weeks after the FDA approved an all-oral regimen for newly diagnosed acute myeloid leukemia (AML), a panel of leukemia ...
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results